A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma

  • Thomas J. Galloway
  • , Lori J. Wirth
  • , Alexander D. Colevas
  • , Jill Gilbert
  • , Julie E. Bauman
  • , Nabil F. Saba
  • , David Raben
  • , Ranee Mehra
  • , Anna W. Ma
  • , Ruzanna Atoyan
  • , Jing Wang
  • , Barbara Burtness
  • , Antonio Jimeno

Research output: Contribution to journal › Article › peer-review

94 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases